

ARIC Manuscript Proposal # 1438

PC Reviewed: 10/14/08
SC Reviewed: _____

Status: A
Status: _____

Priority: 2
Priority: _____

1.a. Full Title: Genome-wide Association Study of Activated Partial Thromboplastin Time (aPTT) and Protein C – the ARIC Study

b. Abbreviated Title (Length 26 characters): GWAS of aPTT and protein C

2. Writing Group: Weihong Tang, Saonli Basu, Aaron Folsom, Xiaoxiao Kong, James Pankow, Nena Aleksic, Eric Boerwinkle, others are welcome...

I, the first author, confirm that all the coauthors have given their approval for this manuscript proposal. ____WT__ **[please confirm with your initials electronically or in writing]**

First author: Weihong Tang, MD, PhD

Address: Division of Epidemiology and Community Health
School of Public Health
University of Minnesota
1300 South Second Street, WBOB 300
Minneapolis, MN 55454

Phone: 612-626-9140

Fax: 612-624-0315

E-mail: tang0097@umn.edu

ARIC author to be contacted if there are questions about the manuscript and the first author does not respond or cannot be located (this must be an ARIC investigator).

Name: Aaron Folsom, MD, MPH

Address: the same as for Dr. Tang

Phone: (612) 626-8862

Fax: (612) 624-0315

E-mail: folso001@umn.edu

3. Timeline: Data analysis to start immediately (October, 2008). First draft of manuscript expected between November, 2008 and February, 2009 depending on the timeline for obtaining replication data for aPTT in the Caerphilly Study, an UK population-based epidemiological study.

4. Rationale:

Venous thromboembolism (VTE) is a common disease with a high mortality rate. It collectively constitutes the third most common life-threatening cardiovascular disease after coronary heart disease and stroke.¹ Both environmental and genetic risk factors, mostly targeting coagulation system, are important in the etiology of VTE.^{2, 3,4,5,6} However, the major genetic variants for VTE have not been identified.

aPTT is a commonly used coagulation test to screen for deficiencies in the coagulation cascade. Protein C is one of the most important anticoagulant regulators of the coagulation pathway. Reduced levels of aPTT and protein C are important risk factors for VTE.⁷⁻¹⁰ In the ARIC Study, the risk of VTE was 2-3 times higher for participants with aPTT below the median value⁸ and 3.3 times higher for 1.1% of participants with plasma level of protein C values <2.0 mg/L at baseline compared with participants with higher values.⁹

Twin and family studies suggest that aPTT and protein C are heritable, with heritability of 0.36-0.50 for protein C^{11,12} and 0.43-0.83 for aPTT.^{11, 12} Genetic linkage analysis identified a region on chromosome 16 that was strongly linked to protein C level in Spanish families.¹³ Since aPTT and protein C are important risk factors and intermediate phenotype for VTE, it is possible that genetic factors influencing the levels of aPTT and protein C also influence the risk of VTE. Therefore, identification of genetic factors for aPTT and protein C may shed light on genetic etiology of VTE.

In ARIC, aPTT and protein C were measured at baseline in the entire cohort of 11,422 whites and 4089 African Americans, providing an excellent opportunity for the proposed study to conduct a genome-wide association study for these traits in a large sample of white and African American participants.

5. Main Hypothesis/Study Questions:

We propose to investigate the associations of genome-wide SNPs with protein C and aPTT in both white and African Americans participants. We hypothesize that there are novel genetic variants that are associated with plasma level of aPTT and protein C in white and African American populations.

6. Design and analysis (study design, inclusion/exclusion, outcome and other variables of interest with specific reference to the time of their collection, summary of data analysis, and any anticipated methodologic limitations or challenges if present).

Population: All white and African American participants with available phenotype (aPTT and protein C) and GWAS data. The analysis will start with Phase 1 and 2 genome-wide SNP data. Phase 3 data is anticipated to arrive soon and will be integrated when it is available. Use of GWAS data in African Americans will follow the CARE procedures. To the best of our knowledge, ARIC is the only CARE cohort that has aPTT data. Protein C was only available in ARIC and a subset of Cardiovascular Health Study (CHS) cohort in the CARE consortium. The sample size for protein C in CHS is limited (~400)^{14, 15} and it is unclear how many African Americans were included in this subset.

Exclusion: Participants reporting anticoagulant use will be excluded.

Outcome: Plasma level of protein C and aPTT.

SNP data: Genotyped and imputed SNPs for whites; genotyped SNPs (1 million) for African Americans. Imputation in African Americans will not be pursued at this stage due to a lack of suitable population and SNP database for imputation in African Americans. When adequate information/data is available for imputation in African Americans, we will consider imputation and analyze imputed SNPs in African Americans.

Covariates: Primary analyses will be adjusted for age, sex, and field center; Multivariate adjustment will be conducted for top SNPs and include age, sex, field center, smoking status (current, former, never), BMI, diabetes, CVD, TG, HDL-C, total cholesterol, alcohol consumption, systolic blood pressure, antihypertensive treatment, and hormone replacement treatment; Latent population substructure will be screened, and if substructure is detected, measures of population substructure (eg, principal components derived from Eigenstrat software) will be included as covariates in the primary analyses.

Statistical analysis: Analysis will be stratified by race. The 2 outcome variables will be analyzed as continuous variables. A multiple linear regression will be used with the covariates and each SNP as the predictor and each outcome variable as the response variable. Outliers and trait distribution will be checked and appropriate transformation will be conducted if necessary. An additive genetic model will be assumed. For genotyped SNPs, the analyses will be conducted using the genetic analysis package PLINK.¹⁶ For imputed SNPs, we will use ProbABEL 0.0-5

(<http://mga.bionet.nsc.ru/~yurii/ABEL/>) that can incorporate dosage information for imputed SNPs into the regression analysis.

Genome-wide significance threshold: We will use Bonferroni adjusted p-value threshold (eg, 5×10^{-8}).

Validation and replication: We have obtained collaboration agreement from the Caerphilly Study, an UK population-based epidemiological study, to provide us aPTT data and DNA samples from this study to replicate the genetic findings for aPTT obtained in the whites of ARIC. In the Caerphilly Study, about 950 subjects had available aPTT measures and DNA samples. We are currently seeking funds to cover cost for the replication study.

7.a. Will the data be used for non-CVD analysis in this manuscript? ☐ Yes
☒ No

b. If Yes, is the author aware that the file ICTDER03 must be used to exclude persons with a value RES_OTH = "CVD Research" for non-DNA analysis, and for DNA analysis RES_DNA = "CVD Research" would be used? ☐

Yes ☐ No

(This file ICTDER03 has been distributed to ARIC PIs, and contains the responses to consent updates related to stored sample use for research.)

8.a. Will the DNA data be used in this manuscript? ☒ Yes
☐ No

8.b. If yes, is the author aware that either DNA data distributed by the Coordinating Center must be used, or the file ICTDER03 must be used to exclude those with value RES_DNA = “No use/storage DNA”?

☒ Yes ☐ No

8.c. If yes, is the author aware that the participants with RES_DNA = ‘not for profit’ restriction must be excluded if the data are used by a for profit group?

☐ Yes ☐ No

(the data will not be used by a for profit group)

9. The lead author of this manuscript proposal has reviewed the list of existing ARIC Study manuscript proposals and has found no overlap between this proposal and previously approved manuscript proposals either published or still in active status. ARIC Investigators have access to the publications lists under the Study Members Area of the web site at: <http://www.csc.unc.edu/ARIC/search.php>

☒ Yes ☐ No

10. What are the most related manuscript proposals in ARIC (authors are encouraged to contact lead authors of these proposals for comments on the new proposal or collaboration)?

1159 Zakai NA et al. Activated Partial Thromboplastin Time and Risk of Incident Venous Thromboembolism.

783 Folsom AR et al. Protein C, Antithrombin III, and Venous Thromboembolism.

11. a. Is this manuscript proposal associated with any ARIC ancillary studies or use any ancillary study data?

☒ Yes ☐ No

11.b. If yes, is the proposal

☒ **A. primarily the result of an ancillary study (list number* 2006.03—Stampede and Geneva genotype funding in whites, and 2007.02 — CARE genotype funding in African Americans).**

☐ **B. primarily based on ARIC data with ancillary data playing a minor role (usually control variables; list number(s)* _____)**

*ancillary studies are listed by number at <http://www.csc.unc.edu/aric/forms/>

12. Manuscript preparation is expected to be completed in one to three years. If a manuscript is not submitted for ARIC review at the end of the 3-years from the date of the approval, the manuscript proposal will expire.

References

1. Goldhaber SZ. Epidemiology of pulmonary embolism and deep vein thrombosis. In: Bloom AL, Forbes, C.D., Thomas, D.P., Tuddenham, E.G.D., editor. *Haemostasis and Thrombosis* (3rd Edition). New York: Churchill Livingstone; 1994. p. 1327-1333.
2. Rosendaal FR. Venous thrombosis: a multicausal disease. *Lancet*. 1999;353:1167-1173.
3. Rosendaal FR. Risk factors for venous thrombotic disease. *Thromb Haemost*. 1999;82:610-619.
4. Anderson FA, Jr., Spencer FA. Risk factors for venous thromboembolism. *Circulation*. 2003;107:19-16.
5. Lowe GD. Can haematological tests predict cardiovascular risk? The 2005 Kettle Lecture. *Br J Haematol*. 2006;133:232-250.
6. Cushman M. Epidemiology and risk factors for venous thrombosis. *Semin Hematol*. 2007;44:62-69.
7. Tripodi A, Chantarangkul V, Martinelli I, Bucciarelli P, Mannucci PM. A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism. *Blood*. 2004;104:3631-3634.
8. Zakai NA, Ohira T, White R, Folsom AR, Cushman M. Activated partial thromboplastin time and risk of future venous thromboembolism. *Am J Med*. 2008;121:231-238.
9. Folsom AR, Aleksic N, Wang L, Cushman M, Wu KK, White RH. Protein C, antithrombin, and venous thromboembolism incidence: a prospective population-based study. *Arterioscler Thromb Vasc Biol*. 2002;22:1018-1022.
10. Koster T, Rosendaal FR, Briet E, van der Meer FJ, Colly LP, Trienekens PH, Poort SR, Reitsma PH, Vandenbroucke JP. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). *Blood*. 1995;85:2756-2761.
11. Souto JC, Almasy L, Borrell M, Gari M, Martinez E, Mateo J, Stone WH, Blangero J, Fontcuberta J. Genetic determinants of hemostasis phenotypes in Spanish families. *Circulation*. 2000;101:1546-1551.
12. Warren DM, Soria JM, Souto JC, Comuzzie A, Fontcuberta J, Blangero J, MacCluer JW, Almasy L. Heritability of hemostasis phenotypes and their correlation with type 2 diabetes status in Mexican Americans. *Hum Biol*. 2005;77:1-15.
13. Buil A, Soria JM, Souto JC, Almasy L, Lathrop M, Blangero J, Fontcuberta J. Protein C levels are regulated by a quantitative trait locus on chromosome 16: results from the Genetic Analysis of Idiopathic Thrombophilia (GAIT) Project. *Arterioscler Thromb Vasc Biol*. 2004;24:1321-1325.
14. Reiner AP, Carty CL, Jenny NS, Nievergelt C, Cushman M, Stearns-Kurosawa DJ, Kurosawa S, Kuller LH, Lange LA. PROC, PROCR, and PROS1 polymorphisms, plasma anticoagulant phenotypes, and risk of cardiovascular disease and mortality in older adults: the Cardiovascular Health Study. *J Thromb Haemost*. 2008.
15. Sakkinen PA, Cushman M, Psaty BM, Kuller LH, Bajaj SP, Sabharwal AK, Boineau R, Macy E, Tracy RP. Correlates of antithrombin, protein C, protein S, and TFPI in a healthy elderly cohort. *Thromb Haemost*. 1998;80:134-139.
16. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet*. 2007;81:559-575.